InvestSMART

Osteopore Limited (ASX:OSX)

ALERT: Price-sensitive ASX Announcement for OSX
Current share price for OSX : $0.005 -0.007 (-58.33%)+
Release
1 Sep 2025 8:27AM
Price at Release
$0.012
Full Release
download
Summary
Osteopore Limited, an Australian-Singaporean regenerative medicine company, announced a strategic investment of AUD 0.5 million to establish OsteoRx, a special purpose vehicle (SPV) aimed at advancing cellular regenerative medicine. This move involves integrating biotech and medtech to drive breakthroughs in tissue regeneration, disease cures, and longevity science. OsteoRx will be led by prominent scientists Dr. Xianmin Zeng and Dr. Brian Kennedy, focusing on unmet needs in age-related degeneration and tissue regeneration. The investment also involves a controlling stake in RxCell Inc., enhancing Osteopore’s presence in the rapidly growing stem cell market. Osteopore aims to leverage this investment to develop innovative therapies that transform healthspan and quality of life, aligning with its leadership in regenerative medicine.
Key Points
  • Osteopore Limited invests AUD 0.5m in establishing OsteoRx.
  • OsteoRx focuses on cellular regeneration and longevity science.
  • Renowned scientists Dr. Xianmin Zeng and Dr. Brian Kennedy to lead OsteoRx.
  • Investment includes a controlling stake in RxCell Inc.
  • Enhances Osteopore's role in the USD 19.34b stem cell market.
  • Aims to develop therapies addressing age-related degeneration.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.